Treating the ineligible: disease modification in people with multiple sclerosis beyond NHS England commissioning policies

ConclusionPersonalised dosing of cladribine avoided severe lymphopenia in all but one patients and was very well tolerated across a large spectrum of disease severity. Our data suggests cladribine may offer benefit people with relapsing and progressive MS alike. The personalised protocol used appears safe, however warrants controlled studies to more definitively assess efficacy and safety, particularly in groups of pwMS who are not eligible for licensed DMT including oral cladribine (Mavenclad®).
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research